You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
Next week at the American Society of Human Genetics annual meeting, LabCorp researchers plan to present results from almost 1,000 triplet pregnancies.
The firm will validate a model system for test development, integrate key test components, and compare Spotlight to other NIPT assays.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.